Affimed (NASDAQ:AFMD) Given Consensus Rating of “Moderate Buy” by Analysts

Affimed (NASDAQ:AFMD) has earned a consensus rating of “Moderate Buy” from the five brokerages that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $13.50.

Separately, StockNews.com assumed coverage on Affimed in a research note on Friday. They set a “sell” rating on the stock.

Institutional Investors Weigh In On Affimed

A number of hedge funds have recently made changes to their positions in AFMD. Northern Trust Corp bought a new position in Affimed during the fourth quarter valued at about $218,000. Intellectus Partners LLC boosted its stake in Affimed by 34.0% in the fourth quarter. Intellectus Partners LLC now owns 126,414 shares of the biopharmaceutical company’s stock valued at $150,000 after acquiring an additional 32,053 shares during the last quarter. Finally, Jane Street Group LLC bought a new position in shares of Affimed during the 3rd quarter valued at approximately $44,000. 30.82% of the stock is currently owned by institutional investors.

Affimed Stock Up 5.0 %

Shares of Affimed stock opened at $0.93 on Friday. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.93 and a quick ratio of 1.93. Affimed has a 52 week low of $0.52 and a 52 week high of $8.95. The business has a 50 day moving average price of $0.83 and a 200-day moving average price of $1.68.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.